Please login to the form below

Not currently logged in
Email:
Password:

Danish biopharma company wins R&D award

Zealand Pharma has won the 2008 European Research & Development Company of the Year Award from Frost & Sullivan

Zealand Pharma A/S has won the 2008 European Research & Development Company of the Year Award from Frost & Sullivan, a global growth consulting firm. Zealand Pharma is involved in the discovery and development of innovative peptide-based drugs. It has been ranked top for demonstrating technological superiority in its field through market analysis based on interviews and extensive secondary research.

"It is an honour to be recognised by Frost & Sullivan", said David Solomon, head of Zealand Pharma A/S. "The European Research & Development Award highlights our company's ongoing achievements in its path to commercialising peptide-based drugs that treat unmet medical need in the areas of diabetes, metabolism, cardiovascular disease and gastrointestinal disorders such as Crohn's disease." 

The award recognises the ability of the company to successfully develop and introduce new technology, formulate a well-designed product family, and make significant product performance contributions to the industry.

All of Zealand's products target diseases and symptoms of significant unmet clinical need and commercial potential. 

Since 1999, Zealand's scientists have built a pipeline that includes five compounds in clinical development, three of which have been out-licensed to pharmaceutical companies, sanofi-aventis, Wyeth and Helsinn Healthcare.

18th March 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics